Attorney Docket No.:

ISPH-0758

Inventors:

Dobie and Freier

Serial No.:

10/643,432

Filing Date:

August 19, 2003

Page 2

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claim 1 (currently amended): A compound 8 to 80 nucleobases in length targeted to a coding region of a nucleic acid molecule encoding human KOX 1(SEO ID NO:12), wherein said compound specifically hybridizes with said nucleic acid molecule encoding KOX 1 and inhibits the expression of KOX 1.

Claim 2 (original): The compound of claim 1 which is an antisense oligonucleotide.

Claim 3 (original): The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified internucleoside linkage.

Claim 4 (original): The compound of claim 3 wherein the modified internucleoside linkage is a phosphorothioate linkage.

Claim 5 (original): The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified sugar moiety.

Claim 6 (original): The compound of claim 5 wherein the modified sugar moiety is a 2'-0-methoxyethyl sugar moiety.

→ PTOBF

Attorney Docket No.:

ISPH-0758

Inventors:

Dobie and Freier

Serial No.:

10/643,432

Filing Date:

August 19, 2003

Page 3

Claim 7 (original): The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified nucleobase.

Claim 8 (original): The compound of claim 7 wherein the modified nucleobase is a 5-methylcytosine.

Claim 9 (original): The compound of claim 2 wherein the antisense oligonucleotide is a chimeric oligonucleotide.

Claim 10 (canceled).

Claim 11 (original): A composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier or diluent.

Claim 12 (original): The composition of claim 11 further comprising a colloidal dispersion system.

Claim 13 (original): The composition of claim 11 wherein the compound is an antisense oligonucleotide.

Claim 14 (original): A method of inhibiting the expression of KOX 1 in cells or tissues comprising contacting said cells or tissues with the compound of claim 1 so that expression of KOX $1\,$ is inhibited.

Claims 15-20 (canceled).